Login to Your Account



Santaris Forms Agreement With Enzon For Oncology

By Cormac Sheridan


Wednesday, August 2, 2006
Santaris Pharma A/S gained commercial validation for its Locked Nucleic Acid (LNA) oligonucleotide analogue chemistry through a co-development and commercialization oncology deal with Enzon Pharmaceuticals. The agreement is worth in excess of $200 million in up-front and milestone payments. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription